Mirum Pharmaceuticals (MIRM) Equity Average (2019 - 2026)

Mirum Pharmaceuticals has reported Equity Average for 8 years, with the latest figure at $278.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 21.42% year-over-year to $278.6 million; the trailing twelve-month figure through Mar 2026 stood at $278.6 million (up 21.42% YoY), and the FY2025 full-year result was $270.2 million, up 13.92% from the prior year.
• Equity Average for Q1 2026 stood at $278.6 million, down from $303.4 million in the prior quarter.
• The five-year high for Equity Average was $303.4 million in Q4 2025, with the low at $109.8 million in Q2 2022.
• Average Equity Average over 5 years is $203.9 million, with a median of $229.4 million recorded in 2025.
• Year-over-year, Equity Average decreased 25.11% in 2022 and jumped 110.95% in 2024.
• Tracing MIRM's Equity Average over 5 years: stood at $155.7 million in 2022, then jumped by 66.3% to $258.9 million in 2023, then fell by 11.61% to $228.8 million in 2024, then jumped by 32.57% to $303.4 million in 2025, then fell by 8.17% to $278.6 million in 2026.
• The last three Equity Average figures came in at $278.6 million (Q1 2026), $303.4 million (Q4 2025), and $273.6 million (Q3 2025), per Business Quant data.

Peer Comparison